MeiraGTx Holdings plc

MeiraGTx Holdings plc is a clinical-stage gene therapy company whose core business involves developing and testing novel treatments for inherited retinal diseases, neurodegenerative disorders, and other conditions. As a biotechnology firm in pre-commercial stages, its research and development pipeline necessitates extensive animal testing to establish safety and efficacy for regulatory submissions. This reliance on animal models is a fundamental and unavoidable component of its business model.

The company’s primary therapeutic candidates, such as those for achromatopsia and Parkinson’s disease, advance through preclinical studies that routinely utilize animal subjects. While specific incident reports or violation records are not cited in the provided evidence, the nature of its operations places it within the broad biotechnology and pharmaceutical sector, where animal testing is a standard, material practice for bringing new therapies to market. There is no public indication that MeiraGTx employs or is developing non-animal testing methods sufficient to replace this core activity.